XNK Therapeutics logo
Svenska
Svenska
  • About XNK Therapeutics
    About XNK Therapeutics
    Close
    • Organisation
      Management
      Board of directors
      Advisors
      Collaborations and partners
    • Career
      Vacant positions
  • Our Science
    Our Science
    Close
    • Introduction to Cell Therapy
      The XNK Technology Platform
      Benefits
      Potential Indications
      Protection of intellectual property
    • Pipeline
      Clinical Trials
      ACP-001
      ISA-HC-NK
    • Research & Development
  • Investors
    Investors
    Close
    • General meetings
  • Media
    Media
    Close
    • Press releases
    • Subscribe
    • Presentations
  • Contact
  • About XNK Therapeutics
    • Organization
      • Management
      • Board of directors
      • Advisors
    • Collaborations and partners
    • Career
      • Vacant positions
  • Our Science
    • Introduction to Cell Therapy
    • The XNK Technology Platform
      • Benefits
      • Potential Indications
      • Protection of intellectual property
    • Pipeline
    • Clinical Trials
      • ACP-001
      • ISA-HC-NK
    • Research & Development
  • Investors
    • General meetings
  • Media
    • Press releases
    • Subscribe
    • Presentations
  • Contact

General meetings

June 2, 2022

Annual General Meeting 2022

For more information, visit the Swedish page.

April 5, 2022

Extra General Meeting April 2022

For more information, visit the Swedish page.

  • Investors
    • General meetings

Subscribe

Read more about our protection of your personal data.

XNK Therapeutics AB

Hälsovägen 7, Novum
141 57 Huddinge
SWEDEN

Email: info@xnktherapeutics.com

© 2022 XNK Therapeutics

  • Cookies
  • Privacy Policy
  • Integritetspolicy avseende aktieägare